deficiency; 5 and Omenn syndrome with large numbers of oligoclonal T cells and eosinophilia. 6 This group of disSevere combined immunodeficiencies are a group of orders is rapidly fatal without allogeneic bone marrow rare genetic disorders characterized by a profound transplantation (BMT). 7 In the absence of an HLA-identical impairment in both cellular and humoral immune funcdonor, T cell-depleted haploidentical BMT is the most tions. This disorder is rapidly fatal without bone mardeveloped treatment option. 8 Different methods of T cell row transplantation. Unfortunately, most children lack depletion have been performed in the past years. 9 Recently, a histocompatible donor. The development of T cell positive selection of CD34 + cells has offered a new method depletion allows for haploidentical transplantation with of T cell depletion. However, alone, it is not sufficient as reduced risk of GVHD. In the present article, we discuss an effective GVHD prophylaxis. We report the case of a the case of a child diagnosed with X-linked severe comchild diagnosed with X-linked SCID in whom haploidentbined immunodeficiency for whom haploidentical periical peripheral blood stem cell (PBSC) transplantation was pheral blood stem cell transplantation was performed performed with positive selection of CD34 + cells followed by selecting CD34-positive cells followed by depletion of by an additional method of specific CD2 + T cell depletion, T cells. Both selection and purging were performed both using the biotin-avidin-mediated system. using immunoselection by the biotin-avidin system (CEPRATE System). The CD34-enriched T celldepleted product contained 5.05 ؋ 10 6 /kg CD34 ϩ cells with only 0.1 ؋ 10 6 /kg CD3 ϩ cells, achieving a T cell depletion of 4.2 log.
The patient, 1 year old at the time of PBSC transplantation in November 1996, was the first son of a 27-year-old woman. A brother of the mother died at 7 months because Severe combined immunodeficiencies (SCID) are a group of a prolonged disease characterized basically by diarrhea. of rare genetic disorders characterized by severe and perHer sister also had a son who died at 7 months because of sistent infections starting in the first months of life.
1 Infants a pulmonary infection. At 3 months the patient was admitdiagnosed with this disease show an absence of T cells and ted to our hospital because of a lung infection. He also natural killer cells, normal or elevated B cell counts and presented an erythema and later he developed diarrhea and hypogammaglobulinemia. Several types of SCID have been recurrent upper airway infections. The immunologic study defined on the basis of enzymatic, genetic, and immunoshowed a very low level of T lymphocytes and NK cells logic criteria; they comprise reticular dysgenesis with and hypogammaglobulinemia. B lymphocytes were present impaired lymphoid, myeloid and erythroid differentiation; 2 absence of both T and B lymphocyte differentiation; 3 selecin a normal number. The patient was diagnosed with Xtive blockade of T cell differentiation (either X-linked linked SCID and, because there was not a histocompatible or autosomal recessive inherited; 4 adenosine deaminase donor, either related or unrelated, haploidentical peripheral blood stem cell transplantation from the mother was planned. was determined by multiplying their frequency by the leukcolony-stimulating factor (Filgastrim, Neupogen, Amgen, ocyte count in the same sample. Thousand Oaks, CA, USA) at doses of 10 g/kg/day subcutaneously for 5 days. Two aphereses were performed. A Conditioning regimen back-up peripheral blood stem cell harvest sample was cryopreserved and the other was washed twice in phosBusulphan (8 mg/kg from day −9 to day −6) and cyclophosphate-buffered saline (PBS) by centrifugation at phamide (100 mg/kg from day −5 to day −2) were given 1500 r.p.m. for 10 min in order to remove excess platelets.
to the patient as conditioning regimen and cyclosporine Afterwards, this product was incubated with a biotinylated (3 mg/kg from day −1) was administered as GVHD prophyantibody (an anti-human anti-CD34 primary antibody, laxis. The patient received G-CSF 5 g/kg/day from day clone 12.8, mouse IgM) in PBS with 0.1% human serum +1 to day +15. albumin and washed again in PBS to remove unbound antibody. Later the antibody-treated cells were passed successively through a column containing avidin-coated beds Results (CEPRATE SC System). In a second phase the CD34 + selected cells were incubated with a CD2 biotinylated antiAphereses body and then they were passed again through a second
The number of CD34 + cells in the aphereses product were column (CEPRATE TCD T cell depletion System, 63.31 × 10 6 /kg. It contained 1.8 × 10 9 /kg CD3 + cells. CELLPRO Europe, Belgium). The CEPRATE TCD system uses a biotinylated murine monoclonal antibody to the pan-T cell antigen, CD2, and a column containing 50 ml of
Results of CD34 selection avidin-conjugated gel to deplete residual T cells from a CD34-enriched product. The system runs on the CEPRATE Prior to incubation with biotinylated CD34 antibody, the instrument and adds 45 min to the total processing time.
number of CD34 The recovery vs CD34 preincubation was 83.68%. The DMSO, and frozen with our previously reported 10 unconpurity and CD3 log depletion were 74.2% and 2.31, trolled-rate freezing method in a methanol bath and later respectively. were stored in the gas phase of liquid nitrogen.
T cell depletion CD34
+ and T cell enumeration After the T cell depletion, CD34 + cells were 33.72 × 10 6 /kg and the CD3 + cells were 0.07 × 10 6 /kg. On analyzing this Cell counts were performed using a Coulter Counter second step separately, the recovery vs CD2 incubation, (Coulter Electronics, Hialeah, FL, USA). A total of 0.5 to CD34 + purity and CD3 log depletion were 84.29, 91 and 1 × 10 6 cells were obtained from the leukapheresis product, 1.87%, respectively. the preincubation fraction and from the absorbed and unabsorbed fractions during the procedure with the first column and from the CD34-enriched/CD2-depleted fraction after
Final results the procedure with the second column. These cells were After the whole procedure (CD34 isolation plus CD2 incubated for 25 min at room temperature with the monodepletion), the yield, purity and log T cell depletion were clonal antibodies 8G12-PE (HPCA-2/CD34) and Leu-4-70.5%, 91% and 4.2, respectively. The final PBSC graft FTIC (CD3) (both from Becton Dickinson, San Agustin de contained 5.05 × 10 6 /kg CD34 + cells and 0.1 × 10 6 /kg Guadalix, Spain). Following incubation, erythrocytes were CD3 + cells. lysed for 7 min at room temperature with a diethylene glycol lysing reagent (FACS Lysing Solution; Becton Dickinson) and washed twice with 0.1% sodium azide in Engraftment and clinical course PBS (CellWASH; Becton Dickinson) and then analyzed by flow cytometry using a FACSort (Becton Dickinson).
The patient showed neutrophil counts greater than 0.5 × 10 9 /l on day +10 and greater than 1.0 × 10 9 /l on day Samples were gated for acquisition using forward angle (FSC) and 90°light-scattering (SSC) properties, excluding +11. This number increased to more than 5.0 × 10 9 /l on day +15 and this level was maintained in the following days. only cell aggregates and debris. Control staining of cells with anti-mouse monoclonal IgG1-FITC/IgG2a-PE was On day +19 the patient showed a platelet number of 19 × 10 9 /l without transfusion support but afterwards plateperformed on each sample. Fifty thousand cells were lets started to decline and no further platelet recovery was increased to 86%. 11 Our patient was conditioned with the regimen that has been reported as the most advisable in obtained. An immunologic study was performed on day +15 showing no evidence of either T lymphocyte or B lymterms of toxicity with the lowest risk of graft rejection.
11
Unfortunately the patient died because of veno-occlusive phocyte recovery. On day +11 the patient was diagnosed with veno-occlusive disease and died on day +35. No sign disease before it was evident whether or not there was total immune recovery. of GVHD was evident during this period.
In conclusion, this two-step procedure achieves a highly CD34 + cell-enriched T cell-depleted product that may be particularly useful in the mismatched or unrelated donor Discussion setting. SCID is a rare disorder characterized by profound impairment in both cellular and humoral immune functions. Until other somatic gene therapy techniques are more developed, Acknowledgement marrow transplantation is the only treatment option. In the present era, transplantation of SCID from histocompatible
We would like to thank Brendan Hayes for his help in translating sibling donor is associated with disease-free survival rates this manuscript.
of greater than 90%.
11 Unfortunately, the great majority of children with SCID lack a histocompatible sibling donor. In recent years with the development of various methods References of marrow T cell depletion, infants with SCID have begun to receive BMT from haploidentical parental donors. The achieve a 2 to 3 log T cell depletion. 9 The main problem
